The global HIV Diagnostics Test Market is estimated to be valued at US$ 14.05 Mn in 2023 and is expected to exhibit a CAGR of 9.0% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
HIV diagnostics tests detect the presence of HIV antibodies or antigens in the blood to confirm, monitor, or evaluate treatment for HIV infection. These tests help in early detection and management of infection.
Market key trends:
Rapid testing is gaining popularity in the HIV diagnostics test market as it provides results within 20 minutes without requiring specialized equipment or highly trained healthcare professionals. The short waiting time makes people more likely to get tested and reduces loss to follow-up. Moreover, rapid testing helps in prompt diagnosis and early linkage to treatment and care.
The global HIV Diagnostics Test Market is segmented on the basis of test type, product, end user, and region. By test type, the market is segmented into antibody tests, viral load tests, CD4 tests, early infant diagnosis tests, and tests for early infection. Among these, the antibody tests segment dominated the market in 2022 and is expected to continue its dominance over the forecast period due to high adoption of HIV screening tests for early detection of HIV.
The Global HIV Diagnostics Test Market Size is expected to witness high growth, exhibiting CAGR of 9.0% over the forecast period, due to increasing prevalence of HIV/AIDS globally.
The global HIV diagnostics test market size is expected to reach US$ 14.05 Mn in 2023.
The North America region is expected to dominate the global HIV diagnostics test market over the forecast period owing to the increasing adoption of HIV diagnostics tests and rising awareness regarding STD testing in the region.
Regionally, North America is expected to account for the largest share in the global HIV diagnostics test market by 2030, owing to increasing prevalence of HIV/AIDS and rapid adoption of advanced diagnostic technologies in the region. According to the Centers for Disease Control and Prevention, in 2020, an estimated 1.2 million people aged 13 and older were living with HIV in the United States.
Key players operating in the HIV Diagnostics Test market are Abbott, Bio-Rad Laboratories, Inc., Hologic, Inc., Siemens Healthineers, Roche AG, Beckman Coulter Inc., OraSure Technologies, Inc., Becton, Dickinson and Company, Merck KGaA, Chembio Diagnostic Systems, Inc., Zyomyx Incorporation, Bristol €“Myers Squibb, Janssen Pharmaceutica NV, QIAGEN N.V., and ViiV Healthcare Ltd.